A Phase 3 interventional study of insulin degludec/liraglutide and liraglutide in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 109 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-01-03.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 — 4 open to participants now, 4 under way, 2 of them phase 3. insulin degludec · Diabetes Mellitus, Type 2.
Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, this one is the 27th largest by enrollment, is one of 6 that started in 2012, is one of 49 in phase 3, and was the 30th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →4 of the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:
Gan and Lee Pharmaceuticals, USA · Sites in Germany
Ages 18–70
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Sites in China
Ages 18–70
Yanbing Li
Ages 18–70
Tonghua Dongbao Pharmaceutical Co.,Ltd
Ages 18–75
By country, each count listing its studies:
insulin degludec: first FDA approval 2015 (RYZODEG 70/30), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
70 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 3 · Phase 3 50 · Phase 4 8
First in 2006; this study’s year is marked. 6 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 438 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 384 across the 70 interventional studies. Of the 64 that completed or were terminated, 51 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
59 of 70 have an industry lead sponsor. The 10 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S: 25 open now, 29 under way, 11 of them phase 3. Of 603 finished, 174 (29%) have results posted.
Among the 643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S, this one is the 118th largest by enrollment of the 428 interventional ones that give a count, is one of 24 that started in 2012, is one of 187 in phase 3, and was the 317th registered.
Novo Nordisk A/S’s Diabetes Mellitus, Type 2 studies by the year they started, since 1997.
1 of the studies testing insulin degludec in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07173712Yanbing LiRegimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novo Nordisk A/S’s 643 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
This trial is conducted in Europe, Oceania and the United States of America (USA).
The aim of the trial is to investigate the efficacy of insulin degludec/liraglutide in controlling glycaemia in adults with type 2 diabetes inadequately controlled on glucagon-like peptide-1 (GLP-1) receptor agonist and OAD therapy.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
This study's enrollment of 438 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Browse Diabetes Mellitus, Type 2 studies →Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: insulin degludec/liraglutide
Drug: liraglutide · Drug: exenatide
Drug pages: Insulin degludec · Liraglutide
Injected subcutaneously (under the skin) once daily. Dose individually adjusted. Subjects will continue their pre-trial OAD treatment without changing the frequency or dose throughout the trial.
Subjects will continue on their pre-trial treatment of liraglutide (Victoza®) (GLP-1 receptor agonist) + OAD without changing the frequency or dose throughout the trial.
Subjects will continue on their pre-trial treatment of exenatide (Byetta®) (GLP-1 receptor agonist) + OAD without changing the frequency or dose throughout the trial.
Change in Glycosylated Haemoglobin (HbA1c) From Baseline (Randomisation, Visit 2)
Time frame: Week 0, week 26
Responders Achieving Pre-defined Target: HbA1c Below 7.0% (53 mmol/Mol)
Percentage of subjects achieving HbA1c below 7.0% after 26 weeks of treatment.
Time frame: Week 26
Responders Achieving Pre-defined Target: HbA1c Below or Equal to 6.5% (48 mmol/Mol)
Percentage of responders achieving pre-defined target for HbA1c - HbA1c ≤ 6.5% (48 mmol/mol).
Time frame: Week 26
Change From Baseline in Body Weight
Mean change in body weight after 26 weeks of treatment.
Time frame: Week 0, week 26
Change From Baseline in Fasting Plasma Glucose (FPG)
Mean change in fasting plasma glucose from baseline, after 26 weeks of treatment.
Time frame: Week 0, week 26
Number of Severe or Minor Hypoglycaemic Episodes
Rate (events per 100 patient years of exposure) of treatment-emergent confirmed hypoglycaemic episodes. The pool of severe and minor hypoglycaemic episodes was referred to as confirmed hypoglycaemic episodes. Severe hypoglycaemia was categorised as an episode requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemic episodes were defined as an episode with symptoms consistent with hypoglycaemia with confirmation by blood glucose \<2.8 mmol/L (50 mg/dL) or PG \<3.1 mmol/L (56 mg/dL), and which was handled by the subject himself/herself, or any asymptomatic blood glucose value \<2.8 mmol/L (50 mg/dL) or PG value \<3.1 mmol/L (56 mg/dL).
Time frame: After 26 weeks of treatment
Number of Adverse Events (AEs)
Rate (events per 100 exposure years) of treatment-emergent adverse events (an event that had onset date (or an increase in severity) on or after the first day of exposure to randomised treatment and no later than 7 days after the last day of randomised treatment) which occurred during the 26 weeks of treatment.
Time frame: After 26 weeks of treatment
Change From Baseline in Patient Reported Outcomes (PROs) Based on the Treatment Related Impact Measure - Diabetes (TRIM-D)
The patient related outcome is calculated based on TRIM-D questionnaire. The TRIM-D questionnaire consists of 5 sub-domains (treatment burden, daily life, diabetes management, compliance and psychological health), where each question is scored to a 1-5-point scale with a higher score indicating a better health state (less negative impact). Mean TRIM-D individual sub-domain scores and total score are later transformed to a 0-100 scale for analysis. The mean change in scores from baseline to 26 weeks for all the individual sub domains and total scores are presented here.
Time frame: Week 0, week 26
Change From Baseline in Patient Reported Outcomes (PROs) Based on Diabetes Treatment Satisfaction Questionnaire (DTSQ).
Mean change in diabetes treatment satisfaction questionnaire (DTSQs) scores from baseline. The scores ranged from 0 to 6. Higher total score on a 0-6 point scale indicates a general higher treatment satisfaction, whereas higher score on perceived frequency of hyperglycaemia and perceived frequency of hypoglycaemia indicate that blood glucose levels are out of the target range.
Time frame: Week 0, week 26
The trial was conducted at 81 sites in 5 countries as follows: Australia: 5 sites; France: 7 sites; Hungary: 4 sites; Slovakia 6 sites; United States: 59 sites.
| Milestone | Insulin Degludec/Liraglutide + Oral Anti Diabetic Drugs (OADs) | Liraglutide or Exenatide + OADs |
|---|---|---|
| Started | 292 | 146 |
| Completed | 276 | 117 |
| Not completed | 16 | 29 |
| Withdrew: Withdrawal criteria | 2 | 14 |
| Withdrew: Adverse event | 1 | 2 |
| Withdrew: Unclassified | 4 | 10 |
| Withdrew: Protocol violation | 9 | 3 |
| percentage of glycosylated haemoglobin | Insulin Degludec/Liraglutide + Oral Anti Diabetic Drugs (OADs) | Liraglutide or Exenatide + OADs |
|---|---|---|
| Change in Glycosylated Haemoglobin (HbA1c) From Baseline (Randomisation, Visit 2) | -1.32 ± 0.05 | -0.37 ± 0.07 |
Percentage of subjects achieving HbA1c below 7.0% after 26 weeks of treatment.
| Percentage | Insulin Degludec/Liraglutide + Oral Anti Diabetic Drugs (OADs) | Liraglutide or Exenatide + OADs |
|---|---|---|
| Responders Achieving Pre-defined Target: HbA1c Below 7.0% (53 mmol/Mol) | 75.3 | 35.6 |
Percentage of responders achieving pre-defined target for HbA1c - HbA1c ≤ 6.5% (48 mmol/mol).
| Percentage | Insulin Degludec/Liraglutide + Oral Anti Diabetic Drugs (OADs) | Liraglutide or Exenatide + OADs |
|---|---|---|
| Responders Achieving Pre-defined Target: HbA1c Below or Equal to 6.5% (48 mmol/Mol) | 63 | 22.6 |
Mean change in body weight after 26 weeks of treatment.
| kg | Insulin Degludec/Liraglutide + Oral Anti Diabetic Drugs (OADs) | Liraglutide or Exenatide + OADs |
|---|---|---|
| Change From Baseline in Body Weight | 2 ± 3.9 | -0.8 ± 3.0 |
Mean change in fasting plasma glucose from baseline, after 26 weeks of treatment.
| mmol/L | Insulin Degludec/Liraglutide + Oral Anti Diabetic Drugs (OADs) | Liraglutide or Exenatide + OADs |
|---|---|---|
| Change From Baseline in Fasting Plasma Glucose (FPG) | -2.98 ± 2.28 | -0.6 ± 2.74 |
Rate (events per 100 patient years of exposure) of treatment-emergent confirmed hypoglycaemic episodes. The pool of severe and minor hypoglycaemic episodes was referred to as confirmed hypoglycaemic episodes. Severe hypoglycaemia was categorised as an episode requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemic episodes were defined as an episode with symptoms consistent with hypoglycaemia with confirmation by blood glucose \<2.8 mmol/L (50 mg/dL) or PG \<3.1 mmol/L (56 mg/dL), and which was handled by the subject himself/herself, or any asymptomatic blood glucose value \<2.8 mmol/L (50 mg/dL) or PG value \<3.1 mmol/L (56 mg/dL).
| events per 100 patient years of exposure | Insulin Degludec/Liraglutide + Oral Anti Diabetic Drugs (OADs) | Liraglutide or Exenatide + OADs |
|---|---|---|
| Number of Severe or Minor Hypoglycaemic Episodes | 281.7 | 12.1 |
Rate (events per 100 exposure years) of treatment-emergent adverse events (an event that had onset date (or an increase in severity) on or after the first day of exposure to randomised treatment and no later than 7 days after the last day of randomised treatment) which occurred during the 26 weeks of treatment.
| events per 100 exposure years | Insulin Degludec/Liraglutide + Oral Anti Diabetic Drugs (OADs) | Liraglutide or Exenatide + OADs |
|---|---|---|
| Number of Adverse Events (AEs) | 410.1 | 364.3 |
The patient related outcome is calculated based on TRIM-D questionnaire. The TRIM-D questionnaire consists of 5 sub-domains (treatment burden, daily life, diabetes management, compliance and psychological health), where each question is scored to a 1-5-point scale with a higher score indicating a better health state (less negative impact). Mean TRIM-D individual sub-domain scores and total score are later transformed to a 0-100 scale for analysis. The mean change in scores from baseline to 26 weeks for all the individual sub domains and total scores are presented here.
| Scores on a scale | Insulin Degludec/Liraglutide + Oral Anti Diabetic Drugs (OADs) | Liraglutide or Exenatide + OADs |
|---|---|---|
| TRIM-D Treatment Burden Score | 10.8 ± 18.8 | 5.7 ± 19.3 |
| TRIM-D Daily Life Score | 6.3 ± 18.4 | 0.8 ± 18.2 |
| TRIM-D Diabetes Management Score | 10.9 ± 21.3 | 4.1 ± 19.8 |
| TRIM-D Compliance Score | 8.9 ± 17.3 | 4.3 ± 15.9 |
| TRIM-D Psychological Health Score | 7.3 ± 14.7 | 1.4 ± 16.5 |
| TRIM-D Total Score | 8.7 ± 12 | 3.1 ± 12.2 |
Mean change in diabetes treatment satisfaction questionnaire (DTSQs) scores from baseline. The scores ranged from 0 to 6. Higher total score on a 0-6 point scale indicates a general higher treatment satisfaction, whereas higher score on perceived frequency of hyperglycaemia and perceived frequency of hypoglycaemia indicate that blood glucose levels are out of the target range.
| Scores on a scale | Insulin Degludec/Liraglutide + Oral Anti Diabetic Drugs (OADs) | Liraglutide or Exenatide + OADs |
|---|---|---|
| Treatment satisfaction scale total | 3.1 ± 5.6 | 1.1 ± 5.0 |
| Hyperglycaemia | -1.8 ± 2.1 | -0.6 ± 1.9 |
| Hypoglycaemia | 0.2 ± 1.7 | -0.1 ± 1.5 |
Collected over Adverse events from the first trial-related activity after the subject had signed the informed consent until the end of the post-treatment follow-up period (week 27) are reported.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Insulin Degludec/Liraglutide +OADs | — | 9/291 (3.1%) | 88/291 (30.2%) |
| Liraglutide or Exenatide + OADs | — | 3/145 (2.1%) | 39/145 (26.9%) |
| Event | Insulin Degludec/Liraglutide +OADs | Liraglutide or Exenatide + OADs |
|---|---|---|
| CholelithiasisHepatobiliary disorders | 0/291 | 1/145 |
| Foot fractureInjury, poisoning and procedural complications | 0/291 | 1/145 |
| SciaticaNervous system disorders | 0/291 | 1/145 |
| Adrenal insufficiencyEndocrine disorders | 1/291 | 0/145 |
| Atrial fibrillationCardiac disorders | 1/291 | 0/145 |
| Cholecystitis acuteHepatobiliary disorders | 1/291 | 0/145 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 1/291 | 0/145 |
| Lacunar infarctionNervous system disorders | 1/291 | 0/145 |
| Non-cardiac chest painGeneral disorders | 1/291 | 0/145 |
| Peripheral artery thrombosisVascular disorders | 1/291 | 0/145 |
| Event | Insulin Degludec/Liraglutide +OADs | Liraglutide or Exenatide + OADs |
|---|---|---|
| NasopharyngitisInfections and infestations | 26/291 | 19/145 |
| Lipase increasedInvestigations | 29/291 | 7/145 |
| HeadacheNervous system disorders | 27/291 | 9/145 |
| Upper respiratory tract infectionInfections and infestations | 18/291 | 8/145 |
| DiarrhoeaGastrointestinal disorders | 13/291 | 8/145 |
| Age, Continuous(years) | Insulin Degludec/Liraglutide + Oral Anti Diabetic Drugs (OADs) | Liraglutide or Exenatide + OADs | Total |
|---|---|---|---|
| Mean | 58.3 ± 9.9 | 58.4 ± 8.8 | 58.3 ± 9.5 |
| Sex: Female, Male(Participants) | Insulin Degludec/Liraglutide + Oral Anti Diabetic Drugs (OADs) | Liraglutide or Exenatide + OADs | Total |
|---|---|---|---|
| Female | 139 | 75 | 214 |
| Male | 153 | 71 | 224 |
| HbA1c(percentage of glycosylated haemoglobin) | Insulin Degludec/Liraglutide + Oral Anti Diabetic Drugs (OADs) | Liraglutide or Exenatide + OADs | Total |
|---|---|---|---|
| Mean | 7.8 ± 0.6 | 7.7 ± 0.6 | 7.8 ± 0.6 |
| Body weight(kg) | Insulin Degludec/Liraglutide + Oral Anti Diabetic Drugs (OADs) | Liraglutide or Exenatide + OADs | Total |
|---|---|---|---|
| Mean | 95.6 ± 16.6 | 95.5 ± 17.3 | 95.5 ± 16.8 |
| Fasting plasma glucose(mmol/L) | Insulin Degludec/Liraglutide + Oral Anti Diabetic Drugs (OADs) | Liraglutide or Exenatide + OADs | Total |
|---|---|---|---|
| Mean | 9 ± 2.1 | 9.4 ± 2.3 | 9.1 ± 2.2 |
Showing the first 100 of 109 sites across 5 countries. Choose a country and city above to see the rest.
Ran from Aug 2012 to primary completion in Mar 2014, 18 months.
Results were first posted in Jul 2018, 4 years 3 months after primary completion. A results delay was requested in Nov 2014.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 18 months is close to that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Insulin degludec · Liraglutide